Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Farmers Insurance
Dow
Harvard Business School
Chinese Patent Office
McKinsey
Federal Trade Commission
Moodys
Cerilliant

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 8,168,655

« Back to Dashboard

Which drugs does patent 8,168,655 protect, and when does it expire?

Patent 8,168,655 protects XIIDRA and is included in one NDA.

This patent has twenty-three patent family members in fifteen countries.
Summary for Patent: 8,168,655
Title:Compositions and methods for treatment of eye disorders
Abstract: The present invention provides compounds and methods for the treatment of LFA-1 mediated diseases. In particular, LFA-1 antagonists are described herein and these antagonists are used in the treatment of LFA-1 mediated diseases. One aspect of the invention provides for diagnosis of an LFA-1 mediated disease and administration of a LFA-1 antagonist, after the patient is diagnosed with a LFA-1 mediated disease. In some embodiments, the LFA-1 mediated diseases treated are dry eye disorders. Also provided herein are methods for identifying compounds which are LFA-1 antagonists.
Inventor(s): Gadek; Thomas (Oakland, CA), Burnier; John (Pacifica, CA)
Assignee: SARcode Bioscience Inc. (Brisbane, CA)
Application Number:11/436,906
Patent Claim Types:
see list of patent claims
Use; Composition; Dosage form; Device; Delivery;

Drugs Protected by US Patent 8,168,655

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Shire Dev Llc XIIDRA lifitegrast SOLUTION/DROPS;OPHTHALMIC 208073-001 Jul 11, 2016 RX Yes Yes ➤ Sign Up ➤ Sign Up TREATMENT OF SIGNS AND SYMPTOMS OF DRY EYE DISEASE (DED) ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 8,168,655

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
8,758,776 Compositions and methods for treatment ➤ Sign Up
8,771,715 Compositions and methods for treatment ➤ Sign Up
9,045,457 Compositions and methods for treatment ➤ Sign Up
8,084,047 Compositions and methods for treatment of eye disorders ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Baxter
Argus Health
Citi
Colorcon
Harvard Business School
Fuji
Moodys
Queensland Health
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.